By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating from Durban, South Africa, by NewsRx correspondents, research stated, "Ion pairing of a fatty acid with an antibiotic may be an effective strategy for formulation optimization of a nanoantibiotic system. The aim of this study was therefore to explore the potential of linoleic acid (LA) as an ion pairing agent to simultaneously enhance encapsulation efficiency and antibacterial activity of triethylamine neutralized vancomycin (VCM) in solid lipid nanoparticles (SLNs)."
Our news editors obtained a quote from the research from the University of KwaZulu-Natal, "The prepared VCM-LA2 conjugate was characterized by Fourier transform-infrared (FT-IR) spectroscopy, log P and binding energy calculations. The shifts in the FT-IR frequencies of -COOH, NH2 and C=O functionalities, an increase in log P value (1.37) and a lower interaction energy between LA and VCM (-125.54 kcal/mol) confirmed the formation of the conjugate. SLNs were prepared by a hot homogenization and ultrasonication method, and characterized for size, polydispersity index (PI), zeta potential (ZP), entrapment efficiency (%EE), surface morphology and physical stability. In vitro antibacterial activity studies against Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) were conducted. Size, PI and ZP for VCM-LA2_SLNs were 102.7 +/- 1.01, 0.225 +/- 0.02 and -38.8 +/- 2.1 (mV) respectively. SLNs were also stable at 4 degrees C for 3 months. %EE for VCM-HCI_SLNs and VCM-LA2_SLN5 were 16.81 +/- 3.64 and 70.73 +/- 5.96 respectively, indicating a significant improvement in encapsulation of the drug through ion pairing with LA. Transmission electron microscopy images showed spherical nanoparticles with sizes in the range of 95-100 nm. After 36 h,VCM-HCshowed no activity against MRSA. However, the minimum inhibitory concentration for VCM-HCl_SLNs and VCM-LA2_SLN5 were 250 and 31.25 mu g/ml respectively against S. aureus, while against MRSA it was 500 and 15.62 mu g/ml respectively. This confirms the enhanced antibacterial activity of VCM-LA2_SLNs over VCM-HCl_SLNs."
According to the news editors, the research concluded: "These findings therefore suggest that VCM-LA2_SLN5 is a promising nanoantibiotic system for effective treatment against both sensitive and resistant S. aureus infections."
For more information on this research see: Ion pairing with linoleic acid simultaneously enhances encapsulation efficiency and antibacterial activity of vancomycin in solid lipid nanoparticles. Colloids and Surfaces B-Biointerfaces, 2014;117():303-311. Colloids and Surfaces B-Biointerfaces can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands (see also Drugs and Therapies).
The news editors report that additional information may be obtained by contacting R.S. Kalhapure, University of KwaZulu Natal, Sch Hlth Sci, Discipline Pharmaceut Sci, ZA-4000 Durban, South Africa. Additional authors for this research include C. Mocktar, D.R. Sikwal, S.J. Sonawane, M.K. Kathiravan, A. Skelton and T. Govender.
Keywords for this news article include: Antibacterial, Antiinfectives, Antimicrobials, Durban, Vancomycin, South Africa, Nanoparticle, Nanotechnology, Drugs and Therapies, Emerging Technologies, Glycopeptide Antibiotics
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC